Gen-Probe's Q3 Revenues Inch Up 1 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Gen-Probe reported after the close of the market Thursday that its third-quarter revenues increased 1 percent as clinical diagnostic sales offset weakness in its blood screening business.

The San Diego-based molecular diagnostics firm brought in total revenues of $122.7 million for the three months ended Sept. 30, up from $121.2 million for the third quarter of 2008. Its clinical diagnostic sales for the quarter were $69.6 million, up from $55.5 million, while its blood screening sales dropped to $45.4 million from $52.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.